GLP-1–Based Drug Tirzepatide Reduces Heart Risk in High-Risk Patients
Journal of Invasive Cardiology - April 23, 2026
"Patients undergoing TAVR often carry a significant cardiometabolic burden, and these results suggest that targeting underlying risk factors with agents like tirzepatide could translate into meaningful clinical benefit,” said Dr. Ibrahim Mortada. “The reduction in serious cardiovascular events without an increase in ischemic or renal complications provides rationale for clinicians to seriously consider adjunctive metabolic therapy.”